These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 37841712)

  • 1. Cost-effectiveness analysis of atezolizumab in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen: a United Kingdom health care perspective.
    Jiang Y; Zhao M; Xi J; Li J; Tang W; Zheng X
    Front Public Health; 2023; 11():1282374. PubMed ID: 37841712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of adjuvant atezolizumab in stage II-IIIA non-small cell lung cancer expressing ≥50% PD-L1: A United Kingdom health care perspective.
    Yip CY; Greystoke A; Abogunrin S; Belleli R; Di Maio D; Rouse P; Jovanoski N
    Lung Cancer; 2023 May; 179():107171. PubMed ID: 36947997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC).
    Ondhia U; Conter HJ; Owen S; Zhou A; Nam J; Singh S; Abdulla A; Chu P; Felizzi F; Paracha N; Sangha R
    J Med Econ; 2019 Jul; 22(7):625-637. PubMed ID: 30836031
    [No Abstract]   [Full Text] [Related]  

  • 4. Cost-Effectiveness Analysis of Atezolizumab versus Platinum-Based Chemotherapy as First-Line Treatment for Patients with Unresectable Advanced Non-small Cell Lung Cancer with PD-L1 Expression Status in Japan.
    Chisaki Y; Nakano H; Minamide J; Yano Y
    Clin Drug Investig; 2023 Nov; 43(11):839-850. PubMed ID: 37891362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of Atezolizumab Combination Therapy for First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer in the United States.
    Criss SD; Mooradian MJ; Watson TR; Gainor JF; Reynolds KL; Kong CY
    JAMA Netw Open; 2019 Sep; 2(9):e1911952. PubMed ID: 31553470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness of First-Line Atezolizumab versus Chemotherapy in Non-Small-Cell Lung Cancer Patients Ineligible for Platinum-Containing Regimens.
    Li LF; Qi R; Wei TT; Feng L; Zhang X; Liu Q
    Risk Manag Healthc Policy; 2024; 17():927-933. PubMed ID: 38628395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.
    Chouaid C; Bensimon L; Clay E; Millier A; Levy-Bachelot L; Huang M; Levy P
    Lung Cancer; 2019 Jan; 127():44-52. PubMed ID: 30642550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of adjuvant atezolizumab for patients with stage II-IIIA PD-L1+ non-small-cell lung cancer.
    Das M; Ogale S; Jovanoski N; Johnson A; Nguyen C; Bhagwakar J; Lee JS
    Immunotherapy; 2023 Jun; 15(8):573-581. PubMed ID: 37021770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of atezolizumab as adjuvant treatment of patients with stage II-IIIA non-small cell lung cancer, PD-L1+≥50% of tumor cells in France: A modeling study.
    Plessala I; Cawston H; Cortes J; Ajjouri R; Le Lay K; Souquet PJ; Chouaid C
    Lung Cancer; 2023 Oct; 184():107316. PubMed ID: 37562344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of atezolizumab plus chemotherapy as first-line treatment for patients with advanced nonsquamous non-small-cell lung cancer in China.
    Shang F; Zhang B; Kang S
    Expert Rev Pharmacoecon Outcomes Res; 2023 Mar; 23(3):337-343. PubMed ID: 36655382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sugemalimab plus chemotherapy vs. chemotherapy for metastatic non-small-cell lung cancer: A cost-effectiveness analysis.
    Liang X; Chen X; Li H; Liu X; Li Y
    Front Public Health; 2023; 11():1054405. PubMed ID: 36923040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-Line Atezolizumab for Metastatic NSCLC with High PD-L1 Expression: A United States-Based Cost-Effectiveness Analysis.
    Peng Y; Zeng X; Peng L; Liu Q; Yi L; Luo X; Li S; Wang L; Qin S; Wan X; Tan C
    Adv Ther; 2021 May; 38(5):2447-2457. PubMed ID: 33821431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-line pembrolizumab in PD-L1 positive non-small-cell lung cancer: A cost-effectiveness analysis from the UK health care perspective.
    Hu X; Hay JW
    Lung Cancer; 2018 Sep; 123():166-171. PubMed ID: 30089590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atezolizumab compared to chemotherapy for first-line treatment in non-small cell lung cancer with high PD-L1 expression: a cost-effectiveness analysis from US and Chinese perspectives.
    Cheng S; Pei R; Li J; Li B; Tang L; Yin T; Liu S
    Ann Transl Med; 2021 Sep; 9(18):1481. PubMed ID: 34734033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sotorasib versus Docetaxel for treatment of US and Chinese patients with advanced non-small-cell lung cancer with KRAS p.G12C-mutated: A cost-effectiveness analysis to inform drug pricing.
    Jiang Y; Zhao M; Liu R; Zheng X
    Medicine (Baltimore); 2023 Dec; 102(50):e36387. PubMed ID: 38115313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of pembrolizumab monotherapy versus chemotherapy for previously untreated advanced non-small cell lung cancer.
    Aziz MIA; Tan LE; Tan WHG; Toh CK; Loke LPY; Pearce F; Ng K
    J Med Econ; 2020 Sep; 23(9):952-960. PubMed ID: 32462958
    [No Abstract]   [Full Text] [Related]  

  • 17. Cost-effectiveness of atezolizumab plus chemotherapy for advanced non-small-cell lung cancer.
    Lin S; Luo S; Zhong L; Lai S; Zeng D; Rao X; Huang P; Weng X
    Int J Clin Pharm; 2020 Aug; 42(4):1175-1183. PubMed ID: 32524512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-line atezolizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer: a cost-effectiveness analysis from China.
    Yang Z; Zhu Y; Xiang G; Hua T; Ni J; Zhao J; Lu Y; Wu Y; Chang F
    Expert Rev Pharmacoecon Outcomes Res; 2021 Oct; 21(5):1061-1067. PubMed ID: 33682554
    [No Abstract]   [Full Text] [Related]  

  • 19. Economic Evaluation of First-Line Camrelizumab for Advanced Non-small-cell Lung Cancer in China.
    Xiang G; Gu L; Chen X; Wang F; Chen B; Zhao J; Lu Y; Chang F; Zhu Y
    Front Public Health; 2021; 9():743558. PubMed ID: 34957008
    [No Abstract]   [Full Text] [Related]  

  • 20. Cost-effectiveness evaluation based on two models of first-line atezolizumab monotherapy and chemotherapy for advanced non-small cell lung cancer with high-PDL1 expression.
    Zhang C; Liu Y; Tan J; Tian P; Li W
    Front Oncol; 2023; 13():1093469. PubMed ID: 36998459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.